Portfolio News
Sofinnova Capital
Nucana plc announces pricing of initial public offering
Nucana plc announces pricing of initial public offering
Related News
Bionyra Pharma Announces First Healthy Volunteers Dosed in Phase 1 Study of BYN-001, a Long-Acting IL-25 Antibody for Atopic Dermatitis
NodThera Inc. Changes Name to Rezera Inc. and Announces Ruvonoflast Phase 3 Development Program
ProQR Announces First Participant Dosed in Phase 1 Study of AX-0811 and Virtual Investor and Analyst Educational Event on September 30, 2026
Rezera Announces Ruvonoflast Met its Primary Inflammation Endpoint and Demonstrated Favorable Safety Profile in RESOLVE-1 Phase 2 Clinical Trial
Neurent Medical Secures €25 Million Growth Debt Facility from Claret Capital Partners to Accelerate Commercial Expansion